Company profile
C21 Investments Inc.
OTC: CXXIF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Vancouver, BCCIK 0000831609Reports USD
#488 of 1,418 Healthcare companies by revenue54th-percentile growth
EA Score
49DFH 71DQ 18GM 41SS 53
v0.1 · 65/100 weight · provisional
↑ operating margin, Piotroski F · ↓ filing timeliness, growth stability
Methodology →Revenue TTM
$32.6M
Rev growth YoY (TTM)
+8.4%
Net income (FY)
-$3.2M
Employees
114
as of 2026-08-20
Market cap
$31.8M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$32.6M$32.6M2026
Net income-$3.2M-$3.2M2026
Operating income$2.3M$2.3M2026
Total assets$54.4M$54.4M2026
Liabilities$29.0M$29.0M2026
Equity$25.4M$25.4M2026
Revenue trend
FY2022 – FY2026 · USD
FY22
FY22
FY23
FY24
FY24
FY25
FY26
Revenue by segment
Filed disclosures · FY2024
By product
Consolidated100%
Corporate0%
By geography
Nevada100%
The read
What is C21 Investments Inc.’s revenue?
C21 Investments Inc. booked $32.6M in FY2026 revenue, growing 8.3% year over year — about the middle of the pack among Healthcare companies we track, at a -9.9% net margin.
Peers · Healthcare
Rapid Micro Biosystems, Inc.46DOrchestra BioMed Holdings, Inc.46DArcus Biosciences, Inc.47DGrown Rogue International Inc.52DStereotaxis, Inc.55CAoxing Pharmaceutical Company, Inc.——Key facts
CEOSonny Newman
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersVancouver, BC
ExchangeOTC: CXXIF
Employees114
IPO date2018-06-22
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.